Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Grifols S.A. (GRFS)

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,375,900
  • Shares Outstanding, K 687,550
  • Annual Sales, $ 6,100 M
  • Annual Income, $ 706,570 K
  • 60-Month Beta 0.59
  • Price/Sales 1.99
  • Price/Cash Flow 10.06
  • Price/Book 1.58
Trade GRFS with:

Options Overview

Details
  • Implied Volatility 54.03%
  • Historical Volatility 34.69%
  • IV Percentile 39%
  • IV Rank 19.68%
  • IV High 140.80% on 05/29/20
  • IV Low 32.76% on 10/13/20
  • Put/Call Vol Ratio 0.67
  • Today's Volume 10
  • Volume Avg (30-Day) 75
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 582
  • Open Int (30-Day) 618

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.25
  • Growth Rate Est. (year over year) +399,500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.81 +21.54%
on 03/10/21
18.11 -0.61%
on 04/08/21
+2.84 (+18.73%)
since 03/09/21
3-Month
14.81 +21.54%
on 03/10/21
20.49 -12.15%
on 01/19/21
-1.60 (-8.16%)
since 01/08/21
52-Week
14.81 +21.54%
on 03/10/21
21.88 -17.73%
on 04/21/20
-1.77 (-8.95%)
since 04/09/20

Most Recent Stories

More News
Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021

, /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United States Securities and Exchange...

GRF : 8.35 (-0.60%)
GRFS : 18.00 (+1.81%)
Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's...

GIKLY : 13.5000 (unch)
GRF : 8.35 (-0.60%)
GRFS : 18.00 (+1.81%)
Grifols installs first-ever DG Reader Net analyzer in North America

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and leader in the development of innovative diagnostic solutions, today...

GIKLY : 13.5000 (unch)
GRF : 8.35 (-0.60%)
GRFS : 18.00 (+1.81%)
Myasthenia Gravis Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The report for Myasthenia Gravis Treatment offers an assiduous analysis of contemporary market trends, driving factors, consumer behavior, key player strategies, product usage and brand positioning. The...

ARGX : 277.96 (-1.09%)
ALPMF : 14.7000 (-0.64%)
AVDL : 8.78 (unch)
BAX : 84.92 (+1.10%)
GSK : 36.65 (+0.52%)
GRFS : 18.00 (+1.81%)
MTZPY : 18.6000 (-0.13%)
NVS : 87.55 (+0.64%)
RARX : 47.99 (-0.03%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the health and well-being of people...

GIKLY : 13.5000 (unch)
GRF : 8.35 (-0.60%)
GRFS : 18.00 (+1.81%)
New Strong Sell Stocks for March 8th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

DY : 97.31 (+4.45%)
BBSI : 71.11 (-0.95%)
GRFS : 18.00 (+1.81%)
JBGS : 32.07 (-0.31%)
COLD : 39.43 (+0.36%)
Moving Average Crossover Alert: Grifols

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

GRFS : 18.00 (+1.81%)
Grifols fosters world's first scientific journal specialized in blood plasma

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P y NASDAQ: GRFS), a global leader in plasma-derived therapies with a more than 100-year track record of contributing to the health and well-being of people,...

GIKLY : 13.5000 (unch)
GRF : 8.35 (-0.60%)
GRFS : 18.00 (+1.81%)
Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS' for fifth consecutive year

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers,...

WORK : 42.29 (+1.49%)
GIKLY : 13.5000 (unch)
GRF : 8.35 (-0.60%)
GRFS : 18.00 (+1.81%)
Is Grifols (GRFS) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

GRFS : 18.00 (+1.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Key Turning Points

3rd Resistance Point 18.66
2nd Resistance Point 18.35
1st Resistance Point 18.17
Last Price 18.00
1st Support Level 17.68
2nd Support Level 17.37
3rd Support Level 17.19

See More

52-Week High 21.88
Fibonacci 61.8% 19.18
Fibonacci 50% 18.34
Last Price 18.00
Fibonacci 38.2% 17.51
52-Week Low 14.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar